Celltrion to deliver three treatments to Peru

Truxima, Herzuma, and Yuflyma won the bids from the Peruvian Ministry of Health and National Workers' Insurance Fund

Celltrion to deliver three treatments to Peru
Dae-Kyu Ahn 1
2024-02-15 11:38:13 powerzanic@hankyung.com
Bio & Pharma


South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru.

Celltrion's Truxima secured an order in tenders conducted by both the Peruvian Ministry of Health (CENARES) and Peru Social Health Insurance (EsSalud).

It will be supplied to CENARES in two installments (500mg) and to EsSalud for a year (100mg), capturing over half of the overall Peruvian market for this drug, encompassing both biosimilar and original versions.

The company also won bids for anticancer biosimilars Herzuma (trastuzumab) for breast and Yuflyma (adalimumab) for the treatment of autoimmune diseases.

These wins grant Celltrion a dominant 53% share of the Peruvian Trastuzumab market and a solid 20% share of the adalimumab market.

Celltrion plans to launch two additional biosimilars in Peru later this year: Remsima SC (subcutaneous injection for autoimmune diseases) in mid-2024 and Vegzelma (for colorectal and non-small cell lung cancer) by year-end.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Peru #Truxima #Herzuma #Yuflyma

Celltrion to supply Remsima SC, Yuflyma to Norway

Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the biosimilar of Humira to Norway. The company has won the Norwegian government's tender for autoimmune disease treatment. It will provide Remsima S

Celltrion, WuXi XDC to develop new antibody-drug conjugates

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC). In December last year, Celltrion inked the contract development and manufacturing services (CDMO) with WuXi XDC to work on the linker and paylo

Celltrion to export three anticancer drugs to Europe

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries including France, Italy, Belgium, and the Netherlands.The company reported successful contracts for the anticancer biosimilars Herzuma (trastuzum

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Group founder and Chairman Seo Jung-jin (left) speaks at J.P. Morgan Healthcare Conference (Courtesy of Celltrion) South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the J.P. Morgan Healthcar
(* comment hide *}